Equity - Narrative (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) shares	Dec. 31, 2023 USD ($) shares	Aug. 31, 2022 shares	Dec. 31, 2021 USD ($)
Equity [Line Items]
Authorized amount (in shares)				10,000,000
Common shares repurchased (in shares)	0
Shares remaining available for repurchase (in shares)	6,874,241
Unsettled repurchases | $	$ 0
Series C cumulative convertible preferred, shares outstanding (in shares)	1,935,400		1,935,400
Series C cumulative convertible preferred, liquidation preference | $	$ 96,770,000		$ 96,770,000
OP unit equivalent in common shares	1.13
Partners capital account, shares issued for units redeemed		3,572	822,627
Partners' capital account, exchanges and conversions | $		$ 18,000	$ 7,800,000
Exchange ratio of partner units (in shares)	1.13
Series C Cumulative Convertible Preferred Stock
Equity [Line Items]
Series C cumulative convertible preferred, shares outstanding (in shares)	1,935,400
Preferred stock, dividend per annum (in dollars per share) | $ / shares	$ 3.25
Series C cumulative convertible preferred, liquidation preference | $	$ 96,770,000
Convertible preferred stock, conversion ratio (in shares)	2.4339
Preferred stock conversion, threshold conversion price percentage (at least)	1.25
Unvested share-based payment awards
Equity [Line Items]
Shares granted (in shares)	25,755	24,008
Grant date fair value | $	$ 225,000	$ 240,000
At-The-Market Program
Equity [Line Items]
Sale of stock, authorized amount (up to) | $					$ 350,000,000